Real-World Use of Maribavir for Cytomegalovirus Infection after HSCT

Modern strategies to reduce morbidity and mortality from cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) include letermovir prophylaxis in seropositive patients and maribavir for resistant or refractory disease. Maribavir is better tolerated than foscarnet or ganciclovir but has a lower barrier to resistance and limited real-world data. To expand the evidence base, researchers retrospectively analyzed data on 126 courses of oral maribavir given to 118 patients for clinically significant CMV infection after HSCT at 37 European centers.